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In 2008, three articles about tuberculosis (TB)
were published in the News and Perspectives sec-
tion of the Journal of the Formosan Medical Associa-
tion, which included the role of neonatal Bacillus
Calmette-Guerin (BCG) vaccination in Taiwan,1
new diagnostic tools for Mycobacterium tuberculo-
sis,2 and emerging problems of extensive drug-
resistant TB.3 The present article deals with iden-
tification of latent TB infection (LTBI) and its
prevention from reactivation of TB. The incidence
in the Western Pacific region for all forms of TB
was 109/100,000 in 2006.4 Some countries in this
area, such as Taiwan and Hong Kong, have begun
to develop strategies to move from middle-burden
to low-burden areas. Meanwhile, Singapore, Japan,
Australia and New Zealand are considering how
to eliminate TB.
In Taiwan, the initial priority for the Directly
Observed Treatment Strategy (DOTS) launched
in April 2006 was smear-positive TB cases. The
coverage rate was up to 90% by June 2007. The
target populations were then expanded to include
culture-positive cases from 2007, and special risk
groups including aboriginal populations, unco-
operative patients, and homeless people, irrespec-
tive of their smear or culture status, from January
2008.5 Significant improvement of indicators for
TB control is summarized in the Table. The sus-
tained increase in successful treatment, decreas-
ing number of TB cases and mortality under the
DOTS, and diagnosis and treatment of LTBI in
high-risk populations are all accelerating Taiwan
into a low-burden country.
One hundred years ago, purified protein de-
rivative for the tuberculin skin test (TST) was 
developed accidentally for diagnosis of LTBI, and
in the following 50 years, numerous longitudi-
nal studies have correlated the size of the TST re-
action with future risk of active TB. In the 1960s,
Dr Ferebee followed up over 10,000 household
contacts and established a correlation between TST
size and active TB development while no Bacillus
Calmette-Guérin (BCG) vaccination was provided
at that time.6 Without treatment, contacts with
TST size > 10 mm developed disease at a rate of 10
to > 20/1000, whereas contacts with TST size
<5mm had a TB rate of around 5/1000. In Canada,
2997 household contacts identified during 1990–
2000 were followed for a median of 6 years.7
Contacts with TST size > 10 mm developed disease
at a rate of up to 80/1000, whereas contacts with
TST size < 5 mm had a rate of around 10/1000.
The background incidence of TB seemed to be
decreasing compared with 50 years ago, but the
risk of TB in contacts with TST size > 10 mm re-
mained consistently high. Children aged ≤10 years
had a higher risk of developing disease without
intervention, and 57% of those with TST size
> 10 mm developed TB eventually.
However, the sensitivity and specificity of the
TST in identifying M. tuberculosis infection was
less than optimal in the population with prior
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BCG vaccination. This was probably because of
antigenic cross-reactivity among purified protein
derivative, BCG vaccine and environmental my-
cobacteria.8 Therefore, the utility of the TST is
highly dependent on TB prevalence in the popula-
tion. Targeted TST for those with a high risk of
LTBI, such as recent contacts of patients with TB, is
recommended, regardless of BCG history.9 In
Taiwan, >90% of the population aged <60 years
have been vaccinated with BCG at least once.
Those aged >20 years might have received BCG
vaccination on two or more occasions. A study
conducted in Taipei, Taiwan has revealed that, in
children without a known contact history, the ef-
fect of BCG on TST size wanes gradually during the
first 6 years after a single neonatal vaccination.10
Another study conducted in Eastern Taiwan, a re-
gion with high TB prevalence, has shown that TST
positivity in children increases with age as a result
of the high rate of exposure to TB.11 Therefore,
even with high coverage of BCG vaccination at
birth, the TST can still be useful in identifying
those children who contact with LTBI and are el-
igible for preventive treatment in Taiwan.
New diagnostic methods such as interferon
gamma release assays (IGRAs) have been investi-
gated for >7 years. There are two commercial prod-
ucts: QuantiFERON®-TB (Cellestis, Carnegie,
Victoria, Australia) and T-SPOT®-TB (Oxford
Immunotec, Abingdon, Oxon, UK). Both of these
use M. tuberculosis-specific antigens that are lacking
in BCG to detect elevation in interferon gamma in
subjects suspicious for LTBI. There is no gold stan-
dard for diagnosis of LTBI, therefore, a meta-analysis
has been conducted to compare the sensitivity and
specificity of the TST and IGRAs.12 The specificity
of IGRAs was better than that of the TST in 14 stud-
ies in BCG-vaccinated populations with very low
risk of TB exposure. However, the specificity was
comparable for IGRAs and the TST in non-BCG-
vaccinated populations. T-SPOT®-TB was more
sensitive than the TST and QuantiFERON®-TB in
detecting active TB cases, acting as a surrogate of
LTBI. A study by Diel et al tried to follow disease
progression in >600 adult TB contacts in Germany
with 46% BCG coverage.13 Forty percent of indi-
viduals were TST-positive when a cutoff size of
5 mm was used, and 18.3% were positive when
the cutoff was 10 mm, whereas 11% of individu-
als were positive by QuantiFERON®-TB. Six un-
treated contacts progressed to active TB within 2
years, and were confirmed by genotyping. Pro-
gression rate in contacts who were positive by
QuantiFERON®-TB test was significantly higher
than in those with a TST size ≥ 5 mm. However,
such a difference was not seen between contacts
who were positive by QuantiFERON®-TB test and
TST size ≥ 10 mm. Future prospective studies are
needed with a larger sample size to reveal the 
relationship between positive IGRA and risk of
active TB, compared with the TST.
The long-term efficacy of isoniazid monother-
apy for LTBI has been documented by studies with
large sample sizes conducted in the 1950s and
1960s.14,15 The effectiveness is influenced by risk of
TB, drug efficacy and treatment adherence. The fol-
lowing are crucial for the success of LTBI treatment:
provision of adequate diagnosis of LTBI among
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Table. Improvement of indicators for tuberculosis (TB) control with increasing coverage of the Directly
Observed Treatment Strategy (DOTS) (2005–2008)
DOTS Treatment New TB
Incidence rate Mortality rate
Yr
coverage in success in cases 
of TB from TB disease
July during smear-positive reported
(/100,000) (/100,000)
the year (%) TB (%) annually
2005 0 63.9 16,472 72.5 4.3
2006 30 66.8 15,378 67.4 3.6
2007 90 70.9 14,480 63.2 3.4
2008 90 –* 14,265 62.0 3.0
*Not yet completed 12 months of follow-up for outcome of TB control.
close contacts; choice of an effective regimen of
suitable duration; and the use of incentives and en-
ablers to improve treatment adherence. Currently,
9 months of therapy with isoniazid is recom-
mended for LTBI treatment in the United States.9
This long-duration treatment for asymptomatic
contacts makes it worthwhile to investigate alter-
native regimens of shorter duration. The currently
available alternative regimens for LTBI treatment
all contain rifamycin, including: 2 months of ri-
fampin plus pyrazinamide; 3 months of rifampin
plus isoniazid; and 4 months of rifampin and 12
once-weekly doses of rifapentine plus isoniazid.
Recently, the completion rates for 4 months of ri-
fampin have been significantly higher than for 9
months of isoniazid in one randomized trial16 and
at least two retrospective evaluations,17,18 with less
or similar toxicity. The propensity for clinically sig-
nificant drug–drug interactions and possible emer-
gence of rifamycin resistance are of concern, and a
large-scale trial to compare the efficacy of rifampin
with that of isoniazid is justified.16–18
In conclusion, it is time to consider seriously
the wider implementation of LTBI treatment in
Taiwan, especially for children with a history of
close contact with a patient with infectious TB. In
the era of decreasing incidence and prevalence of
TB because of the high cure rate with improved
medical care and DOTS, diagnosis and treatment
of LTBI are the next important strategy in acceler-
ating TB elimination. The most cost-beneficial
strategy to identify LTBI cases and provide treat-
ment through effective delivery systems should
be considered in a programmatic way.
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